

A simple and easily applied scoring system based on age and JAK2, CALR, and MPL mutation status accurately predicts the survival of patients with primary myelofibrosis



n=344 patients with primary myelofibrosis



Diagnosis between 2000 and 2013 at MD Anderson Cancer Center



JAK2, CALR, and MPL mutation screening

Triple mutation negative



17%



JAK2^{V617F}



66%

50% cut-off

Low JAK2^{V617F} allele burden

High JAK2^{V617F} allele burden



CALR



12%



MPL



5%



Mutation status

Prognostic model

Age

Mutation status

Median survival

≤65 years

+



>65 years

OR



>65 years

AND



126 months

72 months

35 months